Work

Adjuvant endocrine therapy for hormone receptor-positive, HER2-negative breast cancer: risk stratification, treatment intensification, and clinical management

Year: 2026
Type: article
Abstract: The review summarizes current approaches to adjuvant endocrine therapy for hormone receptor-positive, HER2-negative early breast cancer. It discusses clinicopathological and biological recurrence-risk factors, assessment of endocrine sensitivity, and criteria for treatment intensification. Evidence on extended endocrine therapy, ovarian suppression, aromatase inhibitors, and the addition of CDK4/6 inhibitors is presented. Particular attention is paid to prevention of bone loss, management of adverse events, drug-drug interactions, lifestyle modification, and treatment adherence. Individual treatment selection should account for the expected absolute benefit, toxicity, comorbidities, menopausal status, and patient preferences. Adjuvant endocrine therapy is viewed as a dynamic clinical management process that requires regular assessment of efficacy and safety, prevention of complications, and timely treatment modification.
Language: English
Subfield: Cancer Research
Open Access status: hybrid
OpenAlex ID: W7235997026
FWCI:
Cites: 25
Cited by:
Related to: 10